| Marker Therapeutics is a clinical-stage immuno-oncology company focusing on the development of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Co. is developing three product candidates as part of its multi tumor associated antigen-specific T cell program for: autologous treatment of lymphoma, and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML); and off-the-shelf products in various indications. Co.'s clinical development programs are: MT-401 for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of lymphoma. We show 16 historical shares outstanding datapoints in our MRKR shares outstanding history coverage, used to compute MRKR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MRKR market cap history over the course of time is important for investors
interested in comparing MRKR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MRKR versus a peer is one thing; comparing
MRKR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MRKR can fluctuate over the course of history.
With this page we aim to empower investors researching MRKR by allowing them to research the MRKR market cap history.